Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 6, 2026Oncology nursing forum

Longitudinal Analysis of Psychoneurological Symptoms and the Gut Microbiome in Patients With Melanoma Receiving Immune Checkpoint Inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

GYGee Su YangUHUpendra P. HegdeZGZhe Guan

Discussion

Loading...

Member takes

Overview

Longitudinal study reveals links between gut microbiome shifts, fatigue, and pain in patients on immune checkpoint inhibitors, highlighting gut health as a target to manage treatment symptoms.

Key Points

  • To characterize changes in psychoneurological symptoms over 12 weeks and evaluate their associations with gut microbiome composition in cancer patients initiating immune checkpoint inhibitors.
  • Enrolled 15 patients with solid tumors (n = 9 males, n = 6 females; mean age = 70.9 years) initiating immune checkpoint inhibitor therapy at a single cancer center.
  • Assessed psychoneurological symptoms using self-report questionnaires and profiled gut microbial communities from stool samples via 16S rRNA sequencing at baseline and 12 weeks post-treatment.
  • Applied least absolute shrinkage and selection operator (LASSO) regression models to identify associations between individual symptom scores and log-ratios of genus abundance.
  • Average patient fatigue levels progressively increased during the 12-week treatment timeframe.
  • At 12 weeks post-treatment, fatigue was significantly associated with Oscillibacter (beta = -0.141), Limosilactobacillus (beta = 0.088), and Erysipelotrichaceae (beta = -0.021; all p < 0.05).
  • Pain severity at 12 weeks was significantly associated with Tannerellaceae (beta = -0.011), Bacteroides (beta = 0.474), and Acidaminococcus (beta = 0.193; all p < 0.05).

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/6a9d1df228139818eab20af1https://doi.org/10.1188/26.onf.e26535372
View Full Paper
Ask AI
Bookmark
Share